COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy

Protocol No
IIT-MCGONIGLE-ONA-NEUROPATHY
Principal Investigator
Erin McGonigle
Phase
II
Summary
In this study we want to find out if Xeomin can temporarily change the severity of the nerve pain people experience in their hands or feet when that peripheral neuropathy is caused by Taxane based chemotherapy for the treatment of breast cancer. We want to find out whether the drug Xeomin reduces the symptoms of numbness, tingling, sensitivity to heat/cold and whether it causes any problems (side effects). Xeomin is approved for use in patients by the U.S. Food and Drug Administration for other conditions, but not for patients who have your condition.
Description
Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category